Some Principles Require Principals: Why Banning "Conflicts of Interest" Won't Solve Incentive Problems in Biomedical Research

By Sage, William M. | Texas Law Review, May 2007 | Go to article overview
Save to active project

Some Principles Require Principals: Why Banning "Conflicts of Interest" Won't Solve Incentive Problems in Biomedical Research


Sage, William M., Texas Law Review


I. Introduction: Relational Duties And Regulatory Duties

Money seems to have supplanted state power as the principal concern of biomedical research ethics. Each year brings new illustrations of the tension between financial flows and the moral and legal duties of academic researchers1:

* A young man dies after university-based physicians with a commercial stake in a novel gene therapy ignore warning signs when enrolling research subjects to test the procedure.2

* A pharmaceutical company pressures a university to which it has promised a large gift to demote a researcher who had published research casting the company's products in a negative light.3

* A pharmaceutical company attempts to prevent a university researcher from reporting that, contrary to expectations, its proprietary formulation of a human hormone is not superior to cheaper generics.4

* Another pharmaceutical company pressures the university researchers with whom it has contracts not to publish findings that antidepressant drugs are ineffective and may increase the risk of suicide.5

* A prominent health care provider conducts clinical trials on a new use of a Food and Drug Administration (FDA)-approved radiofrequency ablation device in which the health care provider itself, its physician-CEO, and others had invested. The health care provider publishes its results in peer-reviewed journals, and treats over 1,000 patients with the device "off-label."6

These are serious situations that demand a response from the scientific establishment, the health care professions, and the government. Poorly conducted or managed research can harm research subjects, bias research outcomes, delay dissemination of useful research products, and threaten public trust in, and support of, science.

This Article challenges the legal and ethical language of the response that is occurring and the implications of that language - not the underlying need for current action or future vigilance. Criticism of financial relationships involving biomedical research has been widespread, with individuals, professional associations, and government entities universally labeling them "conflicts of interest." In 2004, the U.S. Department of Health and Human Services issued a detailed guidance document regarding financial conflicts of interest in medical research.7 The guidance includes points for consideration by research institutions, institutional review boards (IRBs), and individual researchers in constituting themselves and with respect to the design and review of specific research protocols. Measures recommended to manage a financial interest include reducing or eliminating the interest, disclosing it to prospective subjects, separating financial from research decisions, independently monitoring research, and modifying the roles for particular individuals or the location of certain activities. In response to such mandates, or as a result of collective professional deliberation, academic research organizations have directed their IRBs to examine research proposals for conflicts of interest, and have chartered conflicts of interest committees to monitor individual and institutional behavior. In general, these bodies are expected to know a conflict of interest when they see one.

The current discussion of research conflicts builds on prior controversies over the commercialization of medicine, most recently involving managed care. In addition to reviewing the medical necessity of treatment, health insurers in the 1980s and 1990s began structuring financial incentives for physicians to promote cost-consciousness in the choice of treatment. Although health policy commentators generally accept the need for fairly allocating scarce resources among needy patients, vesting rationing authority in private insurance companies, which were often commercial enterprises, did not sit easily with the medical profession or the public. Many regarded capitated payment, even seen in its best light, as promoting a population-based medical ethic that was incompatible with the bond between individual physicians and patients that characterized traditional medical ethics.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Some Principles Require Principals: Why Banning "Conflicts of Interest" Won't Solve Incentive Problems in Biomedical Research
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?